Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Constrained proteins and uses therefor (PH tag)


總結

MicroCubes are protein-based vaccines that can accommodate various antigens and elicit strong T-cell responses. They distinguish themselves by unique crystalline organisation, resulting in slow-release of the antigen and self-adjuvanted stimulation of both arms of the immune system.


技術優勢

- Versatile vaccine platform to deliver a wide range of antigens.
- Induce strong antigen-specific cellular and humoral immune responses without additional adjuvant
- Heat, freeze, and protease-resistance facilitates vaccine storage
- Second generation ‘PH-MicroCube’ can accommodate full-length, functional membrane proteins with native structure


技術應用

Vaccine platform


詳細技術說明

The ease of design and versatility of MicroCubes supports their use as a potential generic platform for vaccines against cancer and infectious diseases such as HIV, Hep B, influenza and TB. The superior stability of MicroCubes indicates that they will be particularly suitable in cases where the cold chain is too costly or is impractical to maintain. They have been developed from protein crystals produced by common insect viruses. These crystals function to protect the virus particles and are thus robust and able to package large protein cargoes.

We have engineered MicroCubes to incorporate antigens of interest in place of the virus particles, thereby exploiting their remarkable robustness and multivalent presentation of antigens. Importantly, their capacity to accommodate cargoes of different sizes and structures is unique, and vastly superior to that of traditional virus-like particles. Murine immunisation studies showed no toxic effect of MicroCubes and demonstrated that HIV Gag MicroCubes induce robust Gag-specific humoral and cellular responses. The technology has also demonstrated promising results when applied to the HA hemagglutinin antigen in a murine challenge model of influenza.


合作類型

Licensing


申請日期

21/07/2015 00:00:00


申請號碼

AU2015292261
Others


其他

Monash seeks a partner to optimise and adapt the MicroCube system for application.


ID號碼

2014-029


國家/地區

澳洲

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版